A Clinical Study on the Safety and Efficacy of 9MW2821 in Patients With High-risk Non-muscle-invasive Bladder Cancer (NMIBC) That Have Previously Failed to Intravesical Therapy
Latest Information Update: 19 Aug 2024
At a glance
- Drugs Bulumtatug Furvedotin (Primary)
- Indications Bladder cancer
- Focus Adverse reactions
Most Recent Events
- 19 Aug 2024 New trial record